Komori
Human Metabolome Technologies (6090) · InitiativeAdvanced

Productivity Improvement in Analytical Work

First written in FY2016-Q4. 9 of 20 entries say "Restated". Latest entry: FY2026.

20entries
11years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2017AdvancedFY2020-Q3 – FY2020RestatedFY2021 – FY2022AdvancedFY2023 – FY20262016: 220162017: 220172018: 020182019: 220192020: 320202021: 120212022: 320222023: 120232024: 120242025: 020252026: 52026
Same theme, other companies
AI and robotic transformation of operations and development of DX talentA theme 73 companies write about · 1 as a headwind · 73 as a tailwind

The whole theme swung hardest in 2022: 1 of 8 companies on the "Worse" side.

35 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 73 companies compared. The sentences above are computed from all 73.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「The company will improve productivity through the multifaceted introduction of AI, labor-saving measures using robots, and the effective use of resources through workload leveling via healthcare testing contract services.」

    The company presented productivity initiatives combining the multifaceted introduction of AI, labor-saving measures and workload leveling, in addition to productivity improvements through existing equipment and automation.
  2. FY2026-H1AdvancedAnnual report

    「Manufacturing costs increased because depreciation expenses rose following the introduction of new measurement equipment and investments to reduce labor requirements, and personnel expenses increased because of wage increases and other factors.」

    The company reported the introduction of new measurement equipment and investments to reduce labor requirements, indicating progress in equipment and automation measures aimed at improving productivity.
  3. FY2024RaisedAnnual report

    「In addition to promoting digitalization, including the introduction of a production management system, the company will pursue multifaceted productivity improvements through automation, including the introduction of robots, and by shortening analysis time per unit through the development of high-throughput technologies and methods.」

    In addition to existing measures to shorten measurement times and introduce automation, the company is broadening its initiatives to include a production management system, digitalization, automation, high-throughput technologies, and visualization of processes other than analysis.
  4. FY2023AdvancedAnnual report

    「The company will improve productivity by implementing methods that shorten measurement times and automating part of the production process, while also working to reduce costs.」

    The company specifically identified the implementation of methods that shorten measurement times and the automation of part of the production process as means of improving productivity.
  5. FY2022RestatedAnnual report

    「The company will also improve productivity by implementing methods that shorten measurement times and automating part of the production process.」

    The company specifically identified the implementation of methods that shorten measurement times and the automation of part of the production process as means of improving productivity.
  6. FY2022-Q3RestatedAnnual report

    「Against this backdrop, the Group worked to expand orders in its advanced research and development support business, formerly called the metabolomics business, by conducting energetic sales activities using the Web, while also working to improve sales efficiency and reduce general and administrative expenses.」

    The company continues to pursue efficiency initiatives, including improving sales efficiency.
  7. FY2022-Q2RestatedAnnual report

    「Against this backdrop, the Group worked to expand orders in its advanced research and development support business, formerly called the metabolomics business, by conducting energetic sales activities using the Web, while also working to improve sales efficiency and reduce general and administrative expenses.」

    The company continues to pursue efficiency initiatives, including improving sales efficiency.
  8. FY2021RestatedAnnual report

    「The company expanded its service offerings to increase corporate orders, including for human studies, where demand is expected to grow, and will further improve the productivity of contract metabolomics services through automation and new measurement methods.」

    The company identified expanding its service offerings, automation and productivity improvements through new measurement methods as ongoing initiatives.
  9. FY2020AdvancedAnnual report

    「In production, the metabolomics business improved productivity in measurement and analysis operations, enabling it to meet demand during the third quarter, when demand was expanding, without a significant increase in costs.」

    The company stated that improved productivity in measurement and analysis enabled it to respond to expanding demand in the third quarter without a significant increase in costs.
  10. FY2020-Q3AdvancedAnnual report

    「As a result, sales were ¥990.327 million, and segment profit was ¥495.320 million, partly because the company worked to improve operating efficiency, including the utilization rate.」

    The company reported initiatives to improve operating efficiency through higher utilization rates and other measures, as well as segment profit of ¥495.320 million in the metabolomics business.
  11. FY2020-Q2RestatedAnnual report

    「As a result, sales were ¥453.226 million, and segment profit was ¥127.554 million, partly because the company worked to improve operating efficiency, including the utilization rate.」

    The company continues to improve operating efficiency, including through improved utilization rates. The initiatives to improve efficiency and segment profit of ¥127.554 million are reported, but no comparison with the same period of the previous year is provided.
  12. FY2020-Q1RestatedAnnual report

    「Against this backdrop, the Group continued efforts to expand orders in the metabolomics business, focusing on promotional activities such as exhibiting at academic conferences in Japan and overseas and running campaigns, while also focusing on organizational strengthening to improve sales and production efficiency.」

    The company continues to identify organizational strengthening aimed at improving sales and operating efficiency as an initiative.
  13. FY2019RestatedAnnual report

    「The company is promoting productivity improvements through the standardization of operations and other measures.」

    The company continues to identify the standardization of analysis and testing processes and productivity improvements as initiatives.
  14. FY2017AdvancedAnnual report

    「The gross profit margin was 79.8%, an improvement of 6.7 percentage points from the same period of the previous year. This was mainly due to improved productivity in the measurement and analysis operations of the metabolomics analysis business, among other factors.」

    The company stated that improved productivity in measurement and analysis operations contributed to a 6.7-percentage-point improvement in the gross profit margin.
  15. FY2017-Q2RestatedAnnual report

    「In addition, the company worked to improve the productivity of analysis and testing operations and other activities after receiving samples, and to develop new services.」

    The company continues to improve the productivity of analysis and testing operations and other activities. The development of new services was added as a separate thread.
  16. FY2017-Q1RestatedAnnual report

    「In addition, the company worked to improve the productivity of analysis and testing operations and other activities after receiving samples.」

    The company continues to improve the productivity of analysis and testing operations and other activities.
  17. FY2016-Q4First statedAnnual report

    「The company worked to improve the productivity of analysis and testing operations and other activities after receiving samples.」

    The company identified improving the productivity of business processes as a specific initiative.
Moved together

"Capital investment to expand analytical capabilities and accelerate research and development" moved the same way as this thread, in the same document, in 6 of its 20 moves.

654444★123456
  1. ★This thread
  2. 1Capital investment to expand analytical capabilities and accelerate research and development6×
  3. 2Policy of prioritizing retained earnings and considering future dividends5×
  4. 3Proactive Talent Acquisition and Organizational Revitalization4×
  5. 4Expansion of Orders for the Metabolome Analysis Business4×
  6. 5Development of New Markets Related to Foods with Function Claims and Other Areas4×
  7. 6Improvement in profitability of the metabolome analysis business4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Human Metabolome Technologies yet. It last moved in the General Meetings of Shareholders of 2026-08-25: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Productivity Improvement in Analytical Work | Human Metabolome Technologies,Inc. (6090) | Komori